Assessment of the ability of the Privigen® purification process to deplete thrombogenic factor XIa from plasma.

Background And Objectives: Activated clotting factor FXI (FXIa) has been postulated to play a significant role in thromboembolic events potentially associated with the administration of intravenous immunoglobulin. The purpose of this study was to demonstrate that thrombogenic agents, in particular FXIa and FXI, are depleted or inactivated in Privigen(®) .

Materials And Methods: The ability of the purification process to deplete FXIa from plasma was studied.